SecBot SecBot
SECBOTREPLAY Home › Report › TARS

TARS · Q3 XDEMVY sales $194.6M +64% YoY

Tarsus Pharmaceuticals, Inc · PRESS-RELEASE filed Nov 3, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 3, 2026 at 16:05 ET

Tarsus reported Q3 2026 XDEMVY net product sales of $194.6M, up ~64% YoY and above the $190.8M consensus. However, the GAAP net loss widened to $668.3M ($14.40 per share) vs the $-1.77 consensus estimate, driven by $632.2M in acquired IPR&D expenses from the iRenix and Alkeus acquisitions. The underlying commercial momentum is strong, but the large one-time charges make headline earnings uninformative.

  • XDEMVY net product sales $194.6M in Q3 2026, up ~64% YoY from $118.7M
  • Revenue of $194.6M beat consensus of $190.8M
  • GAAP net loss per share $(14.40) vs consensus $(1.77), driven by $632.2M in acquired IPR&D expenses
  • Gross margin remained consistent at ~93%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access